Sign in

CIK 0001231457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
  1. 4/A Insider Changes in Ownership
  2. 4 Open-market sale 10% owner sold 64,857 shares at an average $2.65 ($171,678)
  3. 4 Planned sale Director sold 1,730 shares at $2.60 ($4,499)
  4. 4 Open-market sale 10% owner sold 75,143 shares at an average $2.62 ($196,609)
  5. 4 Open-market sale 10% owner sold 42,818 shares at $2.09 ($89,614)
  6. 4 Open-market sale 10% owner sold 265,552 shares at an average $2.09 ($554,411)
  7. 4 Open-market sale 10% owner sold 91,630 shares at an average $2.19 ($200,278)
  8. 4 Grant or award Director acquired 39,541 shares (grant or award)
  9. 4 Grant or award Director acquired 39,541 shares (grant or award)
  10. 4 Grant or award Director acquired 39,541 shares (grant or award)
  11. 4 Grant or award Director acquired 39,541 shares (grant or award)
  12. 4 Grant or award President and CEO acquired 34,584 shares (grant or award)
  13. 4 Grant or award Chief Financial Officer acquired 5,072 shares (grant or award)
  14. 4 Grant or award Head of Regulatory acquired 2,723 shares (grant or award)
  15. 4 Grant or award VP, Pharmaceutical Development acquired 15,218 shares (grant or award)
  16. 4 Open-market sale VP, Clinical Trial Operations sold 6,849 shares at $2.12 ($14,520)
  17. 4 Open-market sale General Counsel sold 5,496 shares at $2.12 ($11,652)
  18. 4 Open-market sale Head of Quality sold 4,961 shares at $2.12 ($10,517)
  19. 4 Open-market buy Director bought 6,250 shares
  20. 4 Open-market buy Director bought 6,250 shares

Page 5 of 10 · 190 filings